Sec. 4004. MODERNIZING THE REPORTING OF BIOLOGICAL AND BIOSIMILAR PRODUCTS
614 words·~3 min read·
/statute-compilations/comps-15290/sec-4004A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 4004 MODERNIZING THE REPORTING OF BIOLOGICAL AND BIOSIMILAR PRODUCTS Subtitle B of title XI of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173) is amended— ####
(1)**[**[21 U.S.C. 355 note](/us/usc/t21/s355)**]** in section 1111, as amended by section 3(1) of the Patient Right to Know Drug Prices Act— #####
(A)in the paragraph
(3)inserted by such section 3(1), by striking “an application” and inserting “a biosimilar biological product application”; #####
(B)in the paragraph
(4)inserted by such section 3(1), by inserting “application” before “under section 351(k) of the Public Health Service Act”; #####
(C)in the paragraph
(5)inserted by such section 3(1), by striking “for licensure of a biological product under section 351(k) of the Public Health Service Act” and inserting “under section 351(k) of the Public Health Service Act for licensure of a biological product as biosimilar to, or interchangeable with, a reference product”; #####
(D)in paragraph (7), as redesignated and amended by such section 3(1), by striking “or under section 351(a) of the Public Health Service Act” and inserting “or the owner, or exclusive licensee, of a patent included in a list provided under section 351(l)(3) of the Public Health Service Act”; and #####
(E)in the paragraph
(12)added by such section 3(1), by striking “means a brand name drug for which a license is in effect under section 351(a)” and inserting “has the meaning given such term in section 351(i)”; and ####
(2)in section 1112, as amended by section 3(2) of the Patient Right to Know Drug Prices Act— #####
(A)in subsection (a)— ######
(i)in paragraph (1), by striking “for which a statement under section 351(l)(3)(B)(ii)(I) of the Public Health Service Act has been provided”; ######
(ii)in paragraph (2)— ######
(I)in subparagraph (C)(i), by striking “brand name” and inserting “listed”; and ######
(II)by amending clause
(ii)of subparagraph
(C)to read as follows: > > ### “(ii) > > any of the time periods referred to in section 351(k)(6) of the Public Health Service Act as such period applies to such biosimilar biological product application or to any other biosimilar biological product application based on the same reference product.” > ; #####
(B)in subsection (b)— ######
(i)in the subsection heading, by inserting “or Biosimilar Biological Product Applicant” after “Applicant”; ######
(ii)in paragraph (1)(B), by striking the first sentence and inserting the following: “A biosimilar biological product applicant that has submitted a biosimilar biological product application that references a reference product and another biosimilar biological product applicant that has submitted a biosimilar biological product application that references the same reference product shall each file the agreement in accordance with subsection (c).”; and ######
(iii)in paragraph (2)— ######
(I)by striking “2 generic drug applicants” and inserting “2 or more generic drug applicants”; and ######
(II)by striking “or an agreement between 2 biosimilar biological product applicants regarding the 1-year period referred to in section 351(k)(6)(A) of the Public Health Service Act as it applies to the biosimilar biological product applications with which the agreement is concerned” and inserting “, an agreement between 2 or more biosimilar biological product applicants regarding a time period referred to in section 351(k)(6) of the Public Health Service Act as it applies to the biosimilar biological product, or an agreement between 2 or more biosimilar biological product applicants regarding the manufacture, marketing, or sale of a biosimilar biological product”; and #####
(C)in subsection (c)(2), by inserting “were entered into within 30 days of,” after “condition for,”. # TITLE V OTHER MEDICAID PROVISIONS ## Subtitle A Mandatory Reporting With Respect to Adult Behavioral Health Measures
Connectionstraces to 1
Traces to 1 document
U.S. Code
1 reference not yet in our index
- Pub. L. 108-173
Citation graph
cites case law
Sec. 4004
MODERNIZING THE REPORTING OF BIOLOGICAL AND BIOSIMILAR PRODUCTS
Pub. L.Pub. L. 108-173
Cites 2Cited by 0 across 0 sources